VanEck Pharmaceutical ETF
PPH
54 hedge funds and large institutions have $62.9M invested in VanEck Pharmaceutical ETF in 2021 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 11 reducing their positions, and 4 closing their positions.
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
64% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 11
4% more funds holding
Funds holding: 52 → 54 (+2)
43% less call options, than puts
Call options by funds: $416K | Put options by funds: $731K
51.94% less ownership
Funds ownership: 79.37% → 27.43% (-52%)
67% less capital invested
Capital invested by funds: $188M → $62.9M (-$125M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Osaic Holdings
Scottsdale,
Arizona
|
+$2.27M |
| 2 |
Morgan Stanley
New York
|
+$1.77M |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.18M |
| 4 |
22CM
20/20 Capital Management
Costa Mesa,
California
|
+$1.11M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$519K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$92.7M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$25.7M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
-$13.8M |
| 4 |
BCI
Brinker Capital Investments
Berwyn,
Pennsylvania
|
-$4.83M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$3.69M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
APA
51
American Portfolios Advisors
Holbrook,
New York
| $2.41K | – | – | – |
|
|
SWA
52
SOA Wealth Advisors
New York
| $2K | -$5.56K | -78 | -71% |
|
|
53
BNP Paribas Financial Markets
Paris,
France
| – | -$13.8M | -200,000 | Closed |
|
|
BCI
54
Brinker Capital Investments
Berwyn,
Pennsylvania
| – | -$4.83M | -70,000 | Closed |
|
|
TSS
55
Two Sigma Securities
New York
| – | -$219K | -3,178 | Closed |
|
|
SFS
56
Sowell Financial Services
North Little Rock,
Arkansas
| – | -$7K | -100 | Closed |
|
|
HIA
57
Harbor Investment Advisory
Lutherville,
Maryland
| – | +$143 | +2 | New |
|
58
US Bancorp
Minneapolis,
Minnesota
| – | +$285 | +4 | New |
|
PPH Hedge Fund Activity: Q2 2021 in Review
54 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q2 2021, worth a combined $62.9M — down 67% from $188M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new PPH positions and 4 closed out — a net gain of 3 holders — while 18 added to existing stakes and 11 trimmed.
The largest buyer was Osaic Holdings, adding an estimated $2.27M. The largest seller was Goldman Sachs, cutting an estimated $92.7M.
- 54 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q2 2021, up from 52 in Q1 2021.
- Funds reported $62.9M of VanEck Pharmaceutical ETF stock for Q2 2021, down 67% quarter-over-quarter.
- 7 funds opened new VanEck Pharmaceutical ETF positions in Q2 2021 and 4 closed out, a net change of +3 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q2 2021 was Osaic Holdings, an estimated $2.27M added.
- The largest VanEck Pharmaceutical ETF seller in Q2 2021 was Goldman Sachs, an estimated $92.7M sold.
Based on aggregated 13F filings for Q2 2021.